MedPath

IPRATROPIUM BROMIDE AND ALBUTEROL SULFATE

Ipratropium Bromide and Albuterol Sulfate Inhalation Solution 0.5 mg / 3 mg per 3 mL (RDP)

Approved
Approval ID

e0dee492-8bf9-4360-be9b-9d6ee1ecb256

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Dec 20, 2023

Manufacturers
FDA

Ritedose Pharmaceuticals, LLC

DUNS: 968062294

Products 1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

Ipratropium Bromide and Albuterol Sulfate

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code76204-600
Application NumberANDA202496
Product Classification
M
Marketing Category
C73584
G
Generic Name
Ipratropium Bromide and Albuterol Sulfate
Product Specifications
Route of AdministrationRESPIRATORY (INHALATION)
Effective DateDecember 20, 2023
FDA Product Classification

INGREDIENTS (2)

IPRATROPIUM BROMIDEActive
Quantity: 0.5 mg in 3 mL
Code: J697UZ2A9J
Classification: ACTIR
ALBUTEROL SULFATEActive
Quantity: 2.5 mg in 3 mL
Code: 021SEF3731
Classification: ACTIM

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

IPRATROPIUM BROMIDE AND ALBUTEROL SULFATE - FDA Drug Approval Details